| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 3,151 | 3,272 | 3,324 | 3,450 | 3,710 | 3,728 | 3,742 | 3,871 | 3,625 | 3,645 | 4,366 | 4,302 | 4,033 | 4,226 | 4,694 | 5,242 | 5,234 | 5,377 | 5,539 | 5,830 | 6,108 | 5,951 | 6,432 | 9,300 | 6,071 | 5,802 | 5,987 | 6,089 | 5,844 | 6,218 | 5,731 | 6,481 | 6,514 | 6,907 | 7,339 | 7,434 | 7,628 | 7,679 | 7,783 | 8,052 |
| Expenses | 2,506 | 2,574 | 2,586 | 2,688 | 2,885 | 2,878 | 2,847 | 3,011 | 2,920 | 2,845 | 3,319 | 3,311 | 3,261 | 3,539 | 3,792 | 4,208 | 4,271 | 4,311 | 4,473 | 4,701 | 4,862 | 4,679 | 5,071 | 5,011 | 4,735 | 4,502 | 4,766 | 4,993 | 5,002 | 5,303 | 4,950 | 5,453 | 5,477 | 5,772 | 5,846 | 5,753 | 6,042 | 5,949 | 6,230 | 6,401 |
| EBITDA | 645 | 698 | 738 | 762 | 825 | 851 | 895 | 860 | 704 | 800 | 1,047 | 992 | 772 | 687 | 902 | 1,033 | 963 | 1,066 | 1,066 | 1,130 | 1,247 | 1,271 | 1,361 | 4,290 | 1,335 | 1,300 | 1,220 | 1,096 | 842 | 914 | 781 | 1,027 | 1,037 | 1,135 | 1,493 | 1,681 | 1,585 | 1,730 | 1,553 | 1,652 |
| Operating Profit % | 20 % | 21 % | 22 % | 22 % | 21 % | 22 % | 23 % | 22 % | 18 % | 21 % | 24 % | 22 % | 18 % | 15 % | 19 % | 19 % | 18 % | 20 % | 19 % | 19 % | 20 % | 20 % | 20 % | 21 % | 21 % | 21 % | 19 % | 17 % | 14 % | 14 % | 13 % | 15 % | 14 % | 15 % | 18 % | 21 % | 19 % | 20 % | 19 % | 19 % |
| Depreciation | 85 | 89 | 93 | 99 | 111 | 106 | 110 | 111 | 100 | 131 | 132 | 138 | 157 | 155 | 164 | 163 | 187 | 241 | 243 | 250 | 232 | 256 | 257 | 277 | 266 | 280 | 294 | 299 | 254 | 280 | 298 | 321 | 346 | 327 | 418 | 423 | 354 | 404 | 382 | 419 |
| Interest | 21 | 31 | 68 | 9 | 25 | 21 | 18 | 14 | 14 | 17 | 17 | 19 | 25 | 30 | 35 | 48 | 50 | 50 | 41 | 37 | 32 | 21 | 16 | 20 | 18 | 13 | 10 | 16 | 9 | 15 | 25 | 45 | 56 | 57 | 68 | 76 | 89 | 111 | 113 | 119 |
| Profit Before Tax | 557 | 634 | 631 | 717 | 761 | 786 | 830 | 796 | 649 | 709 | 979 | 902 | 651 | 571 | 787 | 917 | 816 | 863 | 864 | 938 | 1,078 | 1,084 | 1,193 | 4,005 | 1,061 | 1,018 | 968 | 794 | 594 | 679 | 523 | 680 | 730 | 812 | 1,076 | 1,262 | 1,230 | 1,324 | 1,208 | 1,200 |
| Tax | 153 | 162 | 178 | 173 | 206 | 201 | 224 | 218 | 117 | 191 | 198 | 307 | 122 | 116 | 175 | 205 | 231 | 228 | 224 | 233 | 229 | 301 | 386 | 1,058 | 260 | 248 | 271 | 190 | 18 | 159 | 113 | 189 | 224 | 242 | 324 | 323 | 323 | 406 | 391 | 354 |
| Net Profit | 403 | 472 | 453 | 545 | 555 | 585 | 606 | 579 | 532 | 518 | 781 | 595 | 529 | 456 | 611 | 712 | 585 | 636 | 640 | 705 | 849 | 783 | 807 | 2,948 | 801 | 770 | 697 | 604 | 576 | 520 | 410 | 491 | 506 | 570 | 752 | 940 | 907 | 918 | 817 | 846 |
| EPS in ₹ | 13.84 | 16.18 | 7.77 | 9.32 | 9.49 | 9.99 | 10.41 | 9.88 | 9.10 | 8.85 | 13.33 | 10.16 | 9.02 | 7.78 | 10.44 | 12.15 | 9.99 | 10.85 | 10.92 | 12.04 | 14.50 | 13.32 | 13.78 | 50.31 | 13.67 | 13.14 | 11.89 | 10.32 | 9.84 | 8.88 | 6.99 | 8.38 | 8.64 | 9.74 | 12.83 | 16.04 | 15.51 | 15.69 | 14.00 | 14.56 |
Aurobindo Pharma
1,197.10
+8.90
(0.75%)
Market Cap
69,527.80 Cr
EPS
54.16
PE Ratio
19.71
Dividend Yield
0.38 %
Industry
Healthcare52 Week High
1,592.00
52 Week Low
1,010.00
PB Ratio
2.27
Debt to Equity
0.21
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from25 analysts
Company News
View All News
USFDA Identifies Quality Control Issues at Aurobindo Facility5 days ago
The U.S. Food and Drug Administration (USFDA) has reported that Aurobindo's quality control unit's responsibilities and procedures are not fully documented or followed. Additionally, the FDA noted a failure to thoroughly investigate unexplained discrepancies in the company's processes.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,683.60 | #1 4,03,952.00 | 35.21 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 40.74 | |
6,483.00 | 1,72,103.30 | 78.53 | 8,184.00 | 0.89 | 1,600 | 23.05 | 63.44 | |
1,484.20 | 1,19,866.20 | 22.74 | 26,520.70 | 14.17 | 4,155 | 30.28 | 47.86 | |
3,174.70 | 1,07,446.30 | 55.70 | 10,785.70 | 11.59 | 1,656 | 10.91 | 43.82 | |
1,230.10 | 1,02,646.40 | #1 18.15 | 28,905.40 | 12.36 | 5,578 | 21.14 | 62.40 | |
2,432.40 | 1,00,355.60 | 50.56 | 10,615.60 | 19.57 | 1,942 | -10.91 | 44.37 | |
908.60 | 91,426.40 | 19.56 | 19,831.50 | 13.82 | 3,831 | -0.19 | 56.78 | |
1,978.90 | 90,344.90 | 27.54 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 44.10 | |
1,197.10 | #9 69,527.80 | #3 19.71 | #2 29,559.20 | #3 17.55 | #5 3,169 | #8 -10.04 | 50.83 | |
30,795.00 | 65,437.20 | 46.30 | 6,097.20 | 10.80 | 1,201 | 27.83 | 54.40 |
Forecast
Actual
Growth Rate
Revenue Growth
17.55 %
Net Income Growth
64.39 %
Cash Flow Change
2.00 %
ROE
47.91 %
ROCE
46.65 %
EBITDA Margin (Avg.)
35.82 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 12,915 | 15,920 | 16,249 | 21,101 | 26,454 | 28,928 | 33,854 | 33,922 | 39,890 | 45,072 |
| Fixed Assets | 3,706 | 4,180 | 4,834 | 6,521 | 8,475 | 9,397 | 9,374 | 10,532 | 11,024 | 14,493 |
| Current Assets | 8,299 | 10,294 | 9,206 | 12,178 | 15,332 | 16,413 | 19,824 | 18,123 | 21,460 | 23,772 |
| Capital Work in Progress | 420 | 848 | 1,458 | 1,583 | 1,669 | 1,986 | 3,062 | 3,747 | 5,390 | 3,869 |
| Investments | 20 | 123 | 246 | 312 | 360 | 555 | 591 | 997 | 543 | 372 |
| Other Assets | 8,770 | 10,769 | 9,712 | 12,686 | 15,951 | 16,991 | 20,828 | 18,645 | 22,934 | 26,338 |
| Total Liabilities | 12,915 | 15,920 | 16,249 | 21,101 | 26,454 | 28,928 | 33,854 | 33,922 | 39,890 | 45,072 |
| Current Liabilities | 6,136 | 7,840 | 6,606 | 8,666 | 12,021 | 11,385 | 10,665 | 8,156 | 11,494 | 12,199 |
| Non Current Liabilities | 1,596 | 790 | 270 | 753 | 541 | 718 | 1,260 | 1,192 | 1,544 | 3,022 |
| Total Equity | 5,182 | 7,290 | 9,374 | 11,682 | 13,892 | 16,825 | 21,929 | 24,574 | 26,852 | 29,851 |
| Reserve & Surplus | 5,127 | 7,229 | 9,313 | 11,622 | 13,832 | 16,766 | 21,871 | 24,517 | 26,781 | 29,784 |
| Share Capital | 29 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 313 | 340 | -424 | 892 | 666 | 871 | 2,561 | -1,164 | 230 | -1,007 |
| Investing Activities | -1,017 | -1,446 | -1,787 | -1,927 | -2,904 | -1,563 | 597 | -3,211 | -3,971 | -4,242 |
| Operating Activities | 1,237 | 1,420 | 3,279 | 1,955 | 1,651 | 4,381 | 3,329 | 5,017 | 2,387 | 2,435 |
| Financing Activities | 93 | 365 | -1,915 | 864 | 1,919 | -1,947 | -1,365 | -2,969 | 1,814 | 800 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 51.94 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.80 % | 51.82 % | 51.82 % | 51.82 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 18.02 % | 16.73 % | 16.59 % | 16.29 % | 15.33 % |
| DIIs | 10.99 % | 12.72 % | 13.82 % | 15.11 % | 15.83 % | 15.58 % | 16.23 % | 14.89 % | 15.08 % | 15.73 % | 17.94 % | 20.23 % | 23.28 % | 24.77 % | 25.13 % | 25.20 % | 26.23 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 8.71 % | 8.54 % | 9.60 % | 8.99 % | 8.37 % | 8.80 % | 8.65 % | 9.42 % | 8.54 % | 7.01 % | 6.15 % | 5.64 % | 5.52 % | 5.47 % | 5.33 % | 5.52 % | 5.47 % |
| Others | 28.36 % | 26.91 % | 24.74 % | 24.07 % | 23.97 % | 23.79 % | 23.29 % | 23.85 % | 24.54 % | 25.42 % | 24.07 % | 22.29 % | 1.36 % | 1.23 % | 1.13 % | 1.17 % | 1.15 % |
| No of Share Holders | 2,32,634 | 2,43,315 | 3,29,940 | 3,41,568 | 3,38,639 | 3,59,684 | 3,58,459 | 3,69,828 | 3,43,617 | 2,93,214 | 2,59,638 | 2,41,944 | 2,44,575 | 2,38,622 | 2,48,488 | 2,57,962 | 2,69,323 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3.2 | 2.5 | 2.5 | 3 | 4 | 9 | 7.5 | 4.5 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.57 | 0.32 | 0.61 | 0.34 | 0.6 | 1.77 | 0.69 | 0.39 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 26 May 2025 |  Quarterly Result Announcement | NA | 26 May 2025 | 1,216.90 | 1,197.10 |
| 06 Feb 2025 | Quarterly Result Announcement | NA | 06 Feb 2025 | 1,156.60 | 1,191.75 |
| 09 Nov 2024 | Quarterly Result Announcement | NA | 09 Nov 2024 | 1,396.00 | 1,327.55 |
| 29 Aug 2024 |  Annual General Meeting | NA | 29 Aug 2024 | 1,404.35 | 1,564.20 |
| 20 Feb 2024 |  Dividend | ₹ 1.50 /share | 20 Feb 2024 | 1,002.00 | 1,040.50 |
| 20 Nov 2023 | Dividend | ₹ 3.00 /share | 20 Nov 2023 | 936.40 | 1,007.35 |
| 17 Feb 2023 | Dividend | ₹ 3.00 /share | 17 Feb 2023 | 445.05 | 479.90 |
| 07 Jun 2022 | Dividend | ₹ 4.50 /share | 06 Jun 2022 | 529.70 | 522.50 |
| 21 Feb 2022 | Dividend | ₹ 1.50 /share | 18 Feb 2022 | 650.05 | 656.80 |
| 18 Nov 2021 | Dividend | ₹ 1.50 /share | 17 Nov 2021 | 690.05 | 666.55 |
| 30 Aug 2021 | Dividend | ₹ 1.50 /share | 27 Aug 2021 | 856.50 | 709.95 |
| 23 Feb 2021 | Dividend | ₹ 1.50 /share | 22 Feb 2021 | 959.45 | 858.10 |
| 21 Jul 2015 |  Bonus | 1:1 | 20 Jul 2015 | 0.00 | 0.00 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
5 days ago
5 days agoBoard Meeting Intimation for Intimation Of Board Meeting.8 days ago
8 days agoCompliances-Reg.24(A)-Annual Secretarial Compliance9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 13, 2025
May 13, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 30, 2025
Apr 30, 2025Intimation Regarding A Safety Incident On April 27 2025 At Lyfius Pharma Private Limited (A Wholly Owned Stepdown Subsidiary Of The Company).Apr 28, 2025
Apr 28, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 28, 2025
Apr 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 26, 2025
Apr 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 23, 2025
Apr 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 12, 2025
Apr 12, 2025Completion Of US FDA Inspection At Raleigh Plant North Carolina Owned By Aurolife Pharma LLC A Wholly Owned Step-Down Subsidiary Of The CompanyApr 11, 2025
Apr 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 09, 2025
Apr 09, 2025Curateq Biologics Received Marketing Authorization For Dyrupeg™ A Pegylated Filgrastim BiosimilarApr 05, 2025
Apr 05, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 02, 2025
Apr 02, 2025Cautionary Email Received From The Stock Exchanges Regarding Delay In Intimation Of Schedule Of Investors MeetMar 31, 2025
Mar 31, 2025Cautionary Email Received From The Stock Exchanges Regarding Delay In Intimation Of Schedule Of Investors MeetMar 28, 2025
Mar 28, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 28, 2025
Mar 28, 2025Closure of Trading WindowMar 25, 2025
Mar 25, 2025Allotment Of Compulsory Convertible Preference Shares To Dr. Satakarni Makkapati By Curateq Biologics Private Limited A Wholly Owned Subsidiary Of The Company.Mar 21, 2025
Mar 21, 2025Classification Of US FDA Inspection At Unit V Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The Company - Reg.Mar 19, 2025
Mar 19, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 19, 2025
Mar 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 12, 2025
Mar 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2025
Mar 11, 2025Termination Of License Agreement With Hilleman Laboratories Singapore Pte Limited By Auro Vaccines Private LimitedMar 05, 2025
Mar 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 04, 2025
Mar 04, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 01, 2025
Mar 01, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionFeb 28, 2025
Feb 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Feb 20, 2025Classification Of US FDA Inspection At One Of The Warehouses Of Aurobindo Pharma USA Inc. A 100% Subsidiary Of The Company.Feb 20, 2025
Feb 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 19, 2025
Feb 19, 2025Completion Of US FDA Pre-Approval Inspection (PAI) At Eugia Steriles Private Limited A 100% Stepdown Subsidiary Of The CompanyFeb 18, 2025
Feb 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 18, 2025
Feb 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 17, 2025
Feb 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 14, 2025
Feb 14, 2025Curateq Biologics Received Marketing Authorisation For Zefylti® A Filgrastim BiosimilarFeb 13, 2025
Feb 13, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 13, 2025
Feb 13, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 13, 2025
Feb 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 08, 2025
Feb 08, 2025Integrated Filing (Financial)Feb 07, 2025
Feb 07, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 06, 2025
Feb 06, 2025Announcement under Regulation 30 (LODR)-AcquisitionFeb 06, 2025
Feb 06, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 06, 2025
Feb 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 06, 2025
Feb 06, 2025Announcement under Regulation 30 (LODR)-AcquisitionFeb 06, 2025
Feb 06, 2025Unaudited Financial Results For The Quarter And Nine Months Period Ended December 31 2024Feb 06, 2025
Feb 06, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On February 6 2025Feb 06, 2025
Feb 06, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 05, 2025
Feb 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2025
Feb 04, 2025Press Release - Curateq Biologics S.R.O Receives Positive Opinion From CHMP / EMA For DyrupegJan 31, 2025
Jan 31, 2025Technical Indicators
RSI(14)
Neutral 50.83
ATR(14)
Less Volatile 39.63
STOCH(9,6)
Neutral 54.31
STOCH RSI(14)
Neutral 38.59
MACD(12,26)
Bearish -4.01
ADX(14)
Weak Trend 8.50
UO(9)
Bearish 40.31
ROC(12)
0.00
WillR(14)
Neutral -41.29
About Aurobindo Pharma
Aurobindo Pharma Limited (APL) is an Indian pharmaceutical company founded in 1986. It manufactures and markets active pharmaceutical ingredients, generic formulations, and branded pharmaceuticals globally. APL specializes in various therapeutic areas including antibiotics, antiretrovirals, cardiovascular, central nervous system, and gastroenterological products. The company operates 24 manufacturing plants worldwide and has 9 R&D facilities. APL has filed numerous Drug Master Files and Abbreviated New Drug Applications in various countries. The company has expanded through acquisitions and joint ventures in multiple countries, including the UK, Italy, and Portugal. APL has also entered the biosimilars and vaccines markets. The company serves over 150 countries and is among the top 5 manufacturers of semi-synthetic penicillins globally.
Website
Chairperson NameM R Kumar
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
